Andy Plump, Takeda president of R&D (Jeff Rumans)
Takeda spins out a pipeline of ‘interesting but still difficult’ psych drugs in $2B deal as it wraps up a post-merger R&D shakeout
Back at JP Morgan in January, I had a sit-down with Takeda R&D chief Andy Plump, who spelled out plans to license out rights …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
